X-ray Induced Persistent Type I Photodynamic Therapy with Enhanced Hypoxia Tolerance and Chemoradiotherapy DOI
Wei Cheng, Shuai He, Qiushui Chen

et al.

Nano Letters, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

The hypoxic tumor microenvironment (TME), inadequate penetration depth of Vis/NIR light, and lack sustaining reactive oxygen species (ROS) production capability photosensitizers pose significant obstacles to the widespread clinic applications photodynamic therapy (PDT). Herein, we developed a "persistent type I X-PDT" platform simultaneously overcome these three limitations. Such nanoplatform could generate efficient ROS (•OH O2•–) under X-ray irradiation in both normoxic environments. persists cells for more than 4 h, even after source is removed. Notably, persistent X-PDT does not increase levels hypoxia-inducible factor-1 alpha (HIF-1α) vascular endothelial growth factor (VEGF) vitro vivo. Moreover, further enhance radiotherapy efficacy conditions, Pt (IV) prodrug was also introduced, which can be reduced cisplatin selectively cells, functioning only as chemodrug but radiosensitizer.

Language: Английский

X-ray Induced Persistent Type I Photodynamic Therapy with Enhanced Hypoxia Tolerance and Chemoradiotherapy DOI
Wei Cheng, Shuai He, Qiushui Chen

et al.

Nano Letters, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

The hypoxic tumor microenvironment (TME), inadequate penetration depth of Vis/NIR light, and lack sustaining reactive oxygen species (ROS) production capability photosensitizers pose significant obstacles to the widespread clinic applications photodynamic therapy (PDT). Herein, we developed a "persistent type I X-PDT" platform simultaneously overcome these three limitations. Such nanoplatform could generate efficient ROS (•OH O2•–) under X-ray irradiation in both normoxic environments. persists cells for more than 4 h, even after source is removed. Notably, persistent X-PDT does not increase levels hypoxia-inducible factor-1 alpha (HIF-1α) vascular endothelial growth factor (VEGF) vitro vivo. Moreover, further enhance radiotherapy efficacy conditions, Pt (IV) prodrug was also introduced, which can be reduced cisplatin selectively cells, functioning only as chemodrug but radiosensitizer.

Language: Английский

Citations

0